Equibles does not estimate personal net worth.
Get an email with a short summary when Stevanato Group S.p.A. publishes a filing, an earnings call transcript or a press release.
Get STVN alertsMarco Dal Lago is recorded as CFO at Stevanato Group S.p.A. (STVN). Marco Dal Lago has spoken on 19 earnings calls and 3 other investor events across 1 company, most recently for Stevanato Group S.p.A. on November 3, 2026. Stevanato Group S.p.A. is classified in the Medical Instruments & Supplies industry within the Healthcare sector.
“Before I begin, I'd like to clarify that all comparisons refer to the third quarter of 2025. Let's start on page 10. In the third quarter of 2026, revenue grew 8% to $326.1 million, both on a reported basis and organically.”
“As Michael said, just a couple of slides to introduce the company. So, we are a global leading provider for mission-critical solutions for the biopharma industry.”
“We are growing double-digit on the cost and currency rate, and so we plan to move to the end of the year with a double-digit growth on the cost and currency rate, 9% on a reported basis.”
“Before I begin, I'd like to clarify that all comparisons refer to the second quarter of 2025, unless otherwise specified. Let's start on page 10. In the second quarter of 2026, revenue grew 8% to $302 million, both on a reported basis and at a cost and currency raise.”
“As Michael said, just a couple of slides to introduce the company. So we are a global leading provider for mission-critical solutions for the biopharma industry.”
Medical Instruments & Supplies · Healthcare
CFO
